Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Interim / Quarterly Report 2016

Dec 28, 2016

52383_rns_2016-12-28_59619fe6-8887-4dfc-84a6-07b7c7431fd1.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

員工數Employee:241 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣795佰萬元(NTD 795mn) 營業項目Business: 原料藥API(64.25%) 中間體Intermediate(29.80%) 特用化學品 Custom-made chemicals(5.95%)

公司概況Outline

Y2015 Jan-Nov.,2016

洲Europe
37.07% 34.64%

洲America
28.81% 40.87%

洲Asia
21.17% 11.40%
內Taiwan
9.44% 10.65%
他 others
3.51% 2.44%
計Total
100.00% 100.00%

營運概況-IS
--------- --

Unit: K NTD

2016 Q1~Q3 2016 Oct~Nov
營收Sales 1,644,764 211,961
營業成本COGS (938,141) (135,975)
毛利Gross Profit 706,623 75,986
毛利率 GP Ratio 43.0% 35.8%
營業費用Operating Expenses (221,500) (42,671)
營業利益Operating Income 485,123 33,315
營業外損益Non-Operating In/Ex (19,890) 6,162
稅前淨利 Net Profit before Tax 465,233 39,477
所得稅Income Tax (82,390)
本期淨利Net Profit after Tax 382,843

產品組合-Products

Y2013 % Y2014 % Y2015 %
PGA 18.31% PGA 17.49% HOCLQ 21.52%
Di-VANa 16.92% Di-VANa 10.09% PGA 17.14%
S20/38 8.39% LPF.Na 8.74% V.A. 10.64%
V.A. 8.23% S20/38 8.25% LPF.Na 7.48%
LPF.Na 6.58% V.A. 8.15% Di-VaNa 5.41%
PPON 6.53% DBS 4.60% S20/38 4.01%
5-HMT 4.51% 5-HMT 4.12% 5-HMT 3.08%
PEB.Na 3.98% NaVA 3.65% DBS 2.98%
NaVa 3.34% Pent-2 3.64% Pent-2 2.68%
DBS 2.63% M115 3.33% Dulox 2.61%
Total 79.42% Total 72.06% Total 77.55%

Product % Jan~Nov, 2016Sales (NT\$)
HOCLQ Sulfate 34.96 649,202,075
VA Series 13.61 252,608,655
PGA 13.17 244,623,282
Pent-2 / PEB.Na 6.77 125,627,583
S-MMAA / Dulo 5.42 100,645,704
5-HMT / wing 5.33 99,041,880
LPF.Na 4.11 76,285,322

Hydroxychloroquine sulfate

風濕性關節炎藥物 For rheumatoid arthritis treatment

Unit : K NT\$

產品介紹Product

VA series-

Unit : K NT\$

Valproic Acid, Divalproex Sodium, Sodium Valproate

治療癲癇藥物 For epilepsy treatment Di-Va學名藥於2009推出 Di-Va generic came out in 2009

Pyrogallolaldehyde ( PGA) - Benserazide

Unit : K NT\$

產品介紹Product

Pent-2/Pentobarbital Sodium

Unit : K NT\$

鎮定安眠用中間體及原料藥 Intermediate and API for calmative

S-MMAA/Duloxetine

Unit : K NT\$

抗憂鬱症藥物 Antidepressant 2013年底Duloxetine專利到期 Duloxetine's patent expired in the end of 2013

5-HMT/Wing

Unit : K NT\$

愛滋病藥物中間體 For AIDS treatment Intermediates for Ritonavir and Lopinavir

Loxoprofen sodium Unit : K NT\$

抗發炎藥物 日本市場200-300公噸 Anti-inflammatory Japan market:200-300MT

GMP Status(GMP現況)

API CGMP CEP DMF MF DMF
Certified
(TFDA)
(EDQM) (USA) (Japan) (Canada)
Valproic Acid (*) (#) 2003 2004 2003 2008 2008
Allopurinol 2004 2003 2011
Sodium
Valproate
2004 2006
Divalproex
Sodium
(**)(#)
2005 2005 2010
Bisoprolol
Fumarate
2006
Pentobarbital
Sodium
2009 2
011
Propafenone
Hydrochloride
2010 2012 2010 2012 2012
Methylphenidate
HCl
2
011
2014
Duloxetine
Hydrochloride
2012 2014 2010/2011 2016
Thiopental 2012
Loxoprofen
Sodium
Hydrate
2012 2011
Articaine
Hydrochloride
2013 2014 2014
Hydroxychloroquine
Sulfate(#)
2014 2014 2014
Clindamycin
Palmitate
HCl
2011
Cyclophosphamide 2014 2012
Brinzolamide 2015 2015
Probucol 2015 2004 2015
Atomoxetine HCl 2016

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

敬 請 指 教